Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

NCT01732276 is registered in ClinicalTrials.gov with Jiangmen Central Hospital as lead sponsor.

NCT NCT01732276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01732276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Lead sponsor
Jiangmen Central Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2013
Completion date
October 31, 2015
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer